Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

Millot, Frédéric; Baruchel, André; Guilhot, Joëlle; Petit, Arnaud; Leblanc, Thierry; Bertrand, Yves; Mazingue, Françoise; Lutz, Patrick; Vérité, Cécile; Berthou, Christian; Garrigue, Claire; Bernard, Frédéric; Yacouben, Karima; Bordigoni, Pierre; Edan, Christine; Réguerre, Yves; Couillault, G.; Méchinaud, Françoise; Cayuela, Jean‐Michel; Guilhot, F.

doi:10.1200/jco.2010.32.7114

Cited by 137 publications

(166 citation statements)

References 22 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5] Reports in adults indicate that measurement of BCR-ABL1 transcripts 3 months after starting imatinib can predict outcome with better overall survival in patients with a BCR-ABL1/ ABL ratio of ,10% at this time point. 6 In order to address the relevance of this cutoff in the pediatric population in terms of cytogenetic and molecular responses and outcome, we reanalyzed the French Glivec phase 4 study data.…”

Section: Introductionmentioning

confidence: 99%

“…Although imatinib is effective for the majority of children with chronic myeloid leukemia (CML), [1][2][3] 13% to 25% of children have a poor response. [3][4][5] Reports in adults indicate that measurement of BCR-ABL1 transcripts 3 months after starting imatinib can predict outcome with better overall survival in patients with a BCR-ABL1/ ABL ratio of ,10% at this time point.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Millot

Guilhot

Baruchel

et al. 2014

Blood

Self Cite

View full text Add to dashboard Cite

International audienceStudies in adults have shown that an early molecular response to imatinib predicts clinical outcome in chronic myeloid leukemia (CML). We investigated the impact of the BCR-ABL1 transcript level measured 3 months after starting imatinib in a cohort of 40 children with CML. Children with a BCR-ABL1/ABL ratio higher than 10% at 3 months after the start of imatinib had a larger spleen size and a higher white blood cell count compared with those with BCR-ABL1/ABL ≤10%. Children with BCR-ABL1/ABL ≤10% 3 months after starting imatinib had higher rates of complete cytogenetic response and major molecular response at 12 months compared to those with BCR-ABL1/ABL \textgreater10%. With a median follow-up of 71 months (range: 22 to 96), BCR-ABL1/ABL ≤10% correlated with better progression free survival. Thus, early molecular response at 3 months predicts outcome in children treated with imatinib for CML. The study was registered at www.clinicaltrials.gov as NCT00845221

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Millot

Guilhot

Baruchel

et al. 2014

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our data are similar to those previously reported in CML children treated with IM. [5][6][7] The mechanism by which TKI treatment causes a growth delay in children remains unknown. Recently, Hobernicht et al suggested that the BCR-ABL targeted TKIs resulted in a decreased GH secretion at the pituitary level rather than an impaired action on downstream targets.…”

mentioning

confidence: 99%

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

et al. 2012

View full text Add to dashboard Cite

“…27,28 However, imatinib can only control and not 'cure' the disease. Furthermore, the long-term (that is, several decades) effects of TKI usage remain unknown.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Jiang

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell countX30 Â 10 9 /L and plts count X450 Â 10 9 /L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio ¼ 1.7, P ¼ 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

show abstract

Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

Abstract: Imatinib is effective in children with CML in CP with response rates similar to rates reported in adults. The adverse effects are acceptable, but longer follow-up studies are required to fully assess the long-term impact.

Cited by 137 publications

References 22 publications

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Contact Info

Product

Resources

About